medigraphic.com
ISSN 1995-9427 (Print)

2020, Number 1

<< Back Next >>

Invest Medicoquir 2020; 12 (1)

Effectiveness of local release of paclitaxel in reducing coronary stent postimplant restenosis in diabetic patients.

Aroche AR, Sosa SRL, Rodríguez NÁY, Ravelo LK, Vázquez CF, Martínez MJO

Language: Spanish
References: 20
Page:
PDF size: 706.08 Kb.


ABSTRACT

Introduction. Drug-eluting stents have expanded their utility to more complex clinical and angiographic situations than the initial ones. Objective. To assess the effectiveness of Active™ and Active Small™ paclitaxel eluting stent models (Iberhospitex, Barcelona, Spain), in diabetic patients versus identical bare metal stents. Method. Prospective randomized study (2007-2015) at CIMEQ, Havana, Cuba, in 92 diabetic patients followed for three years, who agreed to participate, 48 with paclitaxel eluting stents (PES) and 44 with bare metal stents (SMC). Death, myocardial infarction, new target lesion revascularization and their combination, restenosis and stent thrombosis were considered. Frequency distribution, χ2 test, Fisher's test and T-Test of difference between means, Kaplan-Meier curve and Logarithmic Range Test (Mantel-Cox) were used, with statistical significance (α <0.05). That Research in line with the Helsinki declaration, approved by the local Scientific Council and the researchers without has conflict of interest to declare. Results. Myocardial Infarction during follow-up: SLP (0 )vs. SMC (4.5%), death 4.2% vs. 4.5%, new target lesion revascularization due to restenosis 14.6% vs. 34.1%, and late or very late thrombosis 2.1% vs 4.5%. There were 27 combined major cardiac adverse events, with a significant difference between the SLP group and the SMC group, 18.8% vs. 40.9%, respectively; p = 0.03). Conclusions. Paclitaxel eluting stents are more effective than conventional stents in diabetic patients because they reduce restenosis and major cardiac adverse events combined, with a similar incidence of death, myocardial infarction, and stent thrombosis after 3 years of follow-up.


REFERENCES

  1. Paramasivam G, Devasia T, Jayaram A, Razak A, Rao MS, Vijayvergiya R, et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatol J Cardiol [Internet]. enero de 2020 [citado 6 de junio de 2020];23(1):28-34. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141436/

  2. Abud MA, Padilla LT, Pedernera GO, Spaletra PM, Lamelas PM, Candiello A, et al. Impact diabetes mellitus in patients undergoing percutaneous coronary intervention. Rev Argent Cardiol [Internet]. octubre de 2019 [citado 6 de junio de 2020];87(5):344-51. Disponible en: http://ppct.caicyt.gov.ar/index.php/rac/article/view/15204/pdf

  3. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. BMJ [Internet]. 10 de agosto de 2012 [citado 6 de junio de 2020];345. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415955/

  4. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. American Heart Journal [Internet]. octubre de 2007 [citado 6 de junio de 2020];154(4):688-93. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0002870307005054

  5. Billinger M, Räber L, Hitz S, Stefanini GG, Pilgrim T, Stettler C, et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. American Heart Journal [Internet]. 1 de mayo de 2012 [citado 6 de junio de 2020];163(5):876-886.e2. Disponible en: http://www.sciencedirect.com/science/article/pii/S0002870312000981

  6. Tada T, Kimura T, Morimoto T, Ono K, Furukawa Y, Nakagawa Y, et al. Comparison of Three-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Among Insulin-Treated Diabetic, Non–Insulin-Treated Diabetic, and Non-Diabetic Patients from j-Cypher Registry. The American Journal of Cardiology [Internet]. 15 de abril de 2011 [citado 6 de junio de 2020];107(8):1155-62. Disponible en: http://www.sciencedirect.com/science/article/pii/S0002914910027165

  7. Kedhi E, Généreux P, Palmerini T, McAndrew TC, Parise H, Mehran R, et al. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus: Analysis From 18 Pooled Randomized Trials. J Am Coll Cardiol [Internet]. 27 de mayo de 2014 [citado 6 de junio de 2020];63(20):2111-8. Disponible en: https://www.onlinejacc.org/content/63/20/2111

  8. Cuba. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Diabetes. Estadísticas Mundiales. Factográfico salud [Internet]. 2019 Jun [citado Día Mes Año];5(6):[aprox. 14 p.]. Disponible en:http://files.sld.cu/bmn/files/2019/06/factografico-de-salud-junio-2019.pdf

  9. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2018 [Internet]. La Habana: MINSAP; 2019 [citado 21 mayo 2019]. Disponible en: Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

  10. García E, Serra A, Zueco JJ, Larman M, Rumoroso JR, Moreu J, et al. Long-Term Clinical Performance of Paclitaxel-Eluting Stents Coated Witha Bioactive Polymer (P-5) Containing a Triflusal Derivative: Results of the REWAC Registry. J invasive cardiol 2013;25(8):391-396. Disponible en: https://www.researchgate.net/publication/255178558

  11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical End Points in Coronary Stent Trials. Circulation [Internet]. 1 de mayo de 2007 [citado 7 de junio de 2020];115(17):2344-51. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.106.685 313

  12. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, Mehran R, Finn AV, et al. Autopsy Validation Study of the Academic Research Consortium Stent Thrombosis Definition. J Am Coll Cardiol Intv [Internet]. 1 de mayo de 2011 [citado 7 de junio de 2020];4(5):554-9. Disponible en: https://interventions.onlinejacc.org/content/4/5/554

  13. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, et al. Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. Journal of the American College of Cardiology [Internet]. marzo de 2007 [citado 9 de junio de 2019];49(10):1043-51. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0735109707002161

  14. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis JN, Revtyak G, et al. Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. Cathet Cardiovasc Intervent [Internet]. 1 de octubre de 2008 [citado 9 de junio de 2019];72(4):433-45. Disponible en: http://doi.wiley.com/10.1002/ccd.21618

  15. Lasala J, Cox D, Lewis S, Tadros P, Haas R, Schweiger M, et al. Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention [Internet]. mayo de 2009 [citado 9 de junio de 2019];5(1):67-77. Disponible en: http://www.pcronline.com/eurointervention/19th_issue/11

  16. García E, Serra A, Zueco JJ, Larman M, Rumoroso JR, Moreu J, et al. Long-Term Clinical Performance of Paclitaxel-Eluting Stents Coated With a Bioactive Polymer (P-5) Containing a Triflusal Derivative: Results of the REWAC Registry. J invasive cardiol 2013;25(8):391-396. Disponible en: https://www.researchgate.net/publication/255178558

  17. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, et al. Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. Journal of the American College of Cardiology [Internet]. 19 de febrero de 2008;51(7):708. Disponible en: http://www.onlinejacc.org/content/51/7/708.abstract

  18. Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). European Heart Journal [Internet]. 2 de enero de 2010 [citado 7 de junio de 2020];31(2):177-86. Disponible en: https://academic.oup.com/eurheartj/articlelookup/ doi/10.1093/eurheartj/ehp424

  19. Witzenbichler Bernhard, Wöhrle Jochen, Guagliumi Giulio, Peruga Jan Z., Brodie Bruce R., Dudek Dariusz, et al. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions [Internet]. 1 de abril de 2011 [citado 7 de junio de 2020];4(2):130-8. Disponible en: https://www.ahajournals.org/doi/full/10.1161/circinterventions.110.96024 5

  20. Mancini GBJ, Farkouh M, Verma S. Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update. Current Opinion in Cardiology [Internet]. septiembre de 2017 [citado 8 de junio de 2019];32(5):608-16. Disponible en: http://Insights.ovid.com/crossref?an=00001573-201709000-00018




2020     |     www.medigraphic.com